Minerva Neurosciences (NERV) Enterprise Value (2013 - 2026)
Minerva Neurosciences posted quarterly Enterprise Value of -$78.1 million for Q1 2026, down 348.91% year-on-year from $31.4 million in Q1 2025, and up 5.26% on a QoQ basis from -$82.4 million in Q4 2025.
Minerva Neurosciences (NERV) has 14 years of Enterprise Value data on file, last reported at -$78.1 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 348.91% year-over-year to -$78.1 million; the trailing twelve-month figure through Mar 2026 stood at -$78.1 million (down 348.91% YoY), and the FY2025 full-year result was -$82.4 million, down 283.94% from the prior year.
- Enterprise Value for Q1 2026 stood at -$78.1 million, up from -$82.4 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$12.4 million in Q3 2025 and bottomed at -$82.4 million in Q4 2025.
- The 5-year median for Enterprise Value is -$36.1 million (2023), against an average of -$39.7 million.
- The widest annual swing landed in 2025, when Enterprise Value jumped 53.48%; it then sank 348.91% in 2026.
- A 5-year view of Enterprise Value shows it stood at -$34.7 million in 2022, then decreased by 18.34% to -$41.0 million in 2023, then surged by 47.67% to -$21.5 million in 2024, then tumbled by 283.94% to -$82.4 million in 2025, then grew by 5.26% to -$78.1 million in 2026.
- The last three Enterprise Value figures came in at -$78.1 million (Q1 2026), -$82.4 million (Q4 2025), and -$12.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | -78.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -78.06 Mn |
| Dec 31, 2025 | -82.40 Mn |
| Sep 30, 2025 | -12.39 Mn |
| Jun 30, 2025 | -15.35 Mn |
| Mar 31, 2025 | -17.39 Mn |
| Dec 31, 2024 | -21.46 Mn |
| Sep 30, 2024 | -26.63 Mn |
| Jun 30, 2024 | -30.98 Mn |
| Mar 31, 2024 | -34.92 Mn |
| Dec 31, 2023 | -41.01 Mn |
| Sep 30, 2023 | -47.00 Mn |
| Jun 30, 2023 | -51.90 Mn |
| Mar 31, 2023 | -36.08 Mn |
| Dec 31, 2022 | -34.66 Mn |
| Sep 30, 2022 | -40.32 Mn |
| Jun 30, 2022 | -49.85 Mn |
| Mar 31, 2022 | -55.05 Mn |
| Dec 31, 2021 | -54.10 Mn |
| Sep 30, 2021 | -65.69 Mn |
| Jun 30, 2021 | -74.31 Mn |
| Mar 31, 2021 | -80.24 Mn |
| Dec 31, 2020 | -25.46 Mn |
| Sep 30, 2020 | -32.62 Mn |
| Jun 30, 2020 | -32.35 Mn |
| Mar 31, 2020 | -30.14 Mn |
| Dec 31, 2019 | -45.85 Mn |
| Sep 30, 2019 | -38.01 Mn |
| Jun 30, 2019 | -27.94 Mn |
| Mar 31, 2019 | -30.71 Mn |
| Dec 31, 2018 | -50.33 Mn |
| Sep 30, 2018 | -87.40 Mn |
| Jun 30, 2018 | -68.79 Mn |
| Mar 31, 2018 | -45.23 Mn |
| Dec 31, 2017 | -128.16 Mn |
| Sep 30, 2017 | -96.76 Mn |
| Jun 30, 2017 | -77.57 Mn |
| Mar 31, 2017 | -16.54 Mn |
| Dec 31, 2016 | -82.98 Mn |
| Sep 30, 2016 | -91.85 Mn |
| Jun 30, 2016 | -97.06 Mn |
| Mar 31, 2016 | -44.64 Mn |
| Dec 31, 2015 | -32.20 Mn |
| Sep 30, 2015 | -37.49 Mn |
| Jun 30, 2015 | -35.39 Mn |
| Mar 31, 2015 | -52.20 Mn |
| Dec 31, 2014 | -18.55 Mn |
| Sep 30, 2014 | -23.64 Mn |
| Jun 30, 2014 | -480,009.00 |
| Mar 31, 2014 | -2.14 Mn |
| Dec 31, 2013 | -1.82 Mn |
| Sep 30, 2013 | -1.10 Mn |
| Jun 30, 2013 | -1.48 Mn |